ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses

被引:0
作者
Abhishek D. Garg
Patrizia Agostinis
机构
[1] University of Leuven (KULeuven),Cell Death Research & Therapy (CDRT) Unit, Department for Cellular and Molecular Medicine
来源
Photochemical & Photobiological Sciences | 2014年 / 13卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumours are a form of pseudo-organs with their own microenvironment where the cancer cells nurture a dysfunctional immune environment incapable of inciting anti-tumour immunity. It had been proposed that the only way to counteract such an immune system dysfunction in tumours is by eliciting, therapeutically, a cancer cell death pathway that is accompanied by high immunogenicity and possibly inhibits or reduces the influence of the pro-tumourigenic cytokine signalling. Subsequently, a small and a large-scale screening study as well as several targeted studies found that few, selected anticancer therapeutic regimens are able to induce a promising kind of cancer cell demise called immunogenic cell death (ICD), which can activate the immune system owing to the spatiotemporally defined emission of danger signals. Recently, photodynamic therapy (PDT) utilizing the photosensitiser, hypericin (Hyp), became the first PDT paradigm characterized to be capable of inducing bona fide ICD. In the present perspective, we discuss the various technical, conceptual, and molecular advancements and unprecedented results revealed by Hyp-PDT that have influenced the fields of ICD, ER stress biology, cancer cell death, anti-cancer immune responses, photoimmunology and PDT.
引用
收藏
页码:474 / 487
页数:13
相关论文
共 534 条
[1]  
Hanahan D(2011)Hallmarks of cancer: the next generation Cell 144 646-674
[2]  
Weinberg R A(2006)Cancer despite immunosurveillance: immunoselection and immunosubversion Nat. Rev. Immunol. 6 715-727
[3]  
Zitvogel L(2012)Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1 Nat. Immunol. 13 832-842
[4]  
Tesniere A(2010)Immunity, inflammation, and cancer Cell 140 883-899
[5]  
Kroemer G(2013)Cancer immunogenicity, danger signals, and DAMPs: What, when, and how? Biofactors 39 355-367
[6]  
Chiba S(2012)ER stress-induced inflammation: does it aid or impede disease progression? Trends Mol. Med. 18 589-598
[7]  
Baghdadi M(2010)Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation Biochim. Biophys. Acta 1805 53-71
[8]  
Akiba H(2013)Immunogenic cell death in cancer therapy Annu. Rev. Immunol. 31 51-72
[9]  
Yoshiyama H(2013)Inducers of immunogenic cancer cell death Cytokine Growth Factor Rev. 24 319-333
[10]  
Kinoshita I(2012)Immunogenic cell death and DAMPs in cancer therapy Nat. Rev. Cancer 12 860-875